YKL-40 expression in CD14+ liver cells in acute and chronic injury

被引:20
|
作者
Pizano-Martinez, Oscar [1 ]
Yanez-Sanchez, Irinea [1 ]
Alatorre-Carranza, Pilar [1 ]
Miranda-Diaz, Alejandra [1 ]
Ortiz-Lazareno, Pablo C. [2 ]
Garcia-Iglesias, Trinidad [1 ]
Daneri-Navarro, Adrian [1 ]
Vazquez-Del Mercado, Monica [1 ]
Fafutis-Morris, Mary [1 ]
Delgado-Rizo, Vidal [1 ]
机构
[1] Univ Guadalajara, CUCS, Dept Physiol, Guadalajara 44340, Jalisco, Mexico
[2] Ctr Invest Biomed Occidente IMSS, Div Immunol, Guadalajara 44340, Jalisco, Mexico
关键词
YKL-40; Kupffer cells; Liver cirrhosis; CD14(+) cells; HEPATIC-FIBROSIS; SERUM YKL-40; BETA; TRANSLOCATION; MACROPHAGES; DISEASE;
D O I
10.3748/wjg.v17.i33.3830
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To demonstrate that CD14(+) cells are an important source of the growth factor YKL-40 in acute and chronic liver damage. METHODS: Rats were inoculated with one dose of CCl4 to induce acute damage. Liver biopsies were obtained at 0, 6, 12, 24, 48 and 72 h. For chronic damage, CCl4 was administered three days per week for 6 or 8 wk. Tissue samples were collected, and cellular populations were isolated by liver digestion and purified by cell sorting. YKL-40 mRNA and protein expression were evaluated by real-time polymerase chain reaction and western blot. RESULTS: Acute liver damage induced a rapid increase of YKL-40 mRNA beginning at 12 h. Expression peaked at 24 h, with a 26-fold increase over basal levels. By 72 h however, YKL-40 expression levels had nearly returned to control levels. On the other hand, chronic damage induced a sustained increase in YKL-40 expression, with 7- and 9-fold higher levels at 6 and 8 wk, respectively. The pattern of YKL-40 expression in different subpopulations showed that CD14(+) cells, which include Kupffer cells, are a source of YKL-40 after acute damage at 72 h [0.09 relative expression units (REU)] as well as after chronic injury at 6 wk (0.11 REU). Hepatocytes, in turn, accounted for 0.06 and 0.01 REU after 72 h (acute) or 6 wk (chronic), respectively. The rest of the CD14(-) cells (including T lymphocytes, B lymphocytes, natural killer and natural killer T cells) yielded 0.07 and 0.15 REU at 72 h and 6 wk, respectively. YKL-40 protein expression in liver was detected at 72 h as well as 6 and 8 wk, with the highest expression relative to controls (11-fold; P <= 0.05) seen at 6 wk. Macrophages were stimulated by lipopolysaccharide. We demonstrate that under these conditions, these cells showed maximum expression of YKL-40 at 12 h, with P < 0.05 compared with controls. CONCLUSION: Hepatic CD14(+) cells are an YKL-40 mRNA and protein source in acute and chronic liver injury, with expression patterns similar to growth factors implicated in inflammation-fibrogenesis. (C) 2011 Baishideng. All rights reserved.
引用
收藏
页码:3830 / 3835
页数:6
相关论文
共 50 条
  • [21] In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases
    Bonneh-Barkay, Dafna
    Wang, Guoji
    Starkey, Adam
    Hamilton, Ronald L.
    Wiley, Clayton A.
    JOURNAL OF NEUROINFLAMMATION, 2010, 7
  • [22] Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients
    Hall, Isaac E.
    Stern, Edward P.
    Cantley, Lloyd G.
    Elias, Jack A.
    Parikh, Chirag R.
    BMC NEPHROLOGY, 2014, 15 : 133
  • [23] YKL-40 expression in abnormal invasive placenta cases
    Gozukara, Ilay
    Ozgur, Tumay
    Dolapcioglu, Kenan
    Gungoren, Arif
    Karapinar, Oya Soylu
    JOURNAL OF PERINATAL MEDICINE, 2017, 45 (05) : 571 - 575
  • [24] Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients
    Isaac E Hall
    Edward P Stern
    Lloyd G Cantley
    Jack A Elias
    Chirag R Parikh
    BMC Nephrology, 15
  • [25] YKL-40 expression in pterygium: a potential role in the pathogenesis
    Kurt, Ali
    Kilic, Rasit
    Tad, Murat
    Polat, Osman Ahmet
    INTERNATIONAL OPHTHALMOLOGY, 2019, 39 (07) : 1445 - 1450
  • [26] Increased YKL-40 expression in patients with carotid atherosclerosis
    Michelsen, Annika E.
    Rathcke, Camilla N.
    Skjelland, Mona
    Holm, Sverre
    Ranheim, Trine
    Krohg-Sorensen, Kirsten
    Klingvall, Marit F.
    Brosstad, Frank
    Oie, Erik
    Vestergaard, Henrik
    Aukrust, Pal
    Halvorsen, Bente
    ATHEROSCLEROSIS, 2010, 211 (02) : 589 - 595
  • [27] Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression
    Tiriveedhi, Venkataswarup
    Upadhya, Gundumi A.
    Busch, Rebecca A.
    Gunter, Kristen L.
    Dines, Jeff N.
    Knolhoff, Bret L.
    Jia, Jianluo
    Sarma, Nayan J.
    Ramachandran, Sabarinathan
    Anderson, Christopher D.
    Mohanakumar, Thallachallour
    Chapman, William C.
    TRANSPLANT IMMUNOLOGY, 2014, 30 (2-3) : 93 - 98
  • [28] YKL-40 expression in pterygium: a potential role in the pathogenesis
    Ali Kurt
    Raşit Kılıç
    Murat Tad
    Osman Ahmet Polat
    International Ophthalmology, 2019, 39 : 1445 - 1450
  • [29] High serum YKL-40 in patients with liver fibrogenesis.
    Johansen, JS
    Moller, S
    Christoffersen, P
    Price, PA
    Henriksen, JH
    Bendtsen, F
    GASTROENTEROLOGY, 1997, 112 (04) : A1294 - A1294
  • [30] Significance of YKL-40 in comparison to Fibroscan Elastography in Staging liver Fibrosis in Chronic Hepatitis C
    Jabeen, Rakhshinda
    Jami, Ajmaal
    Saeed, Afzal
    Naeem, Syed Talha
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2020, 14 (04): : 1379 - 1382